Trial · NCT00908141
Adverse events100
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 100
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal pain or cramping | Gastrointestinal disorders | Group A: Sargramostim (Days 1-14) | 1 | 8 | |
| other | Abdominal pain or cramping | Gastrointestinal disorders | Group B: Sargramostim (3 x Week) | 1 | 9 | |
| other | Alopecia | Skin and subcutaneous tissue disorders | Group A: Sargramostim (Days 1-14) | 1 | 8 | |
| other | Alopecia | Skin and subcutaneous tissue disorders | Group B: Sargramostim (3 x Week) | 0 | 9 | |
| other | Anxiety | Psychiatric disorders | Group A: Sargramostim (Days 1-14) | 1 | 8 | |
| other | Anxiety | Psychiatric disorders | Group B: Sargramostim (3 x Week) | 0 | 9 | |
| other | Arthralgia (joint pain) | Musculoskeletal and connective tissue disorders | Group A: Sargramostim (Days 1-14) | 0 | 8 | |
| other | Arthralgia (joint pain) | Musculoskeletal and connective tissue disorders | Group B: Sargramostim (3 x Week) | 1 | 9 | |
| other | Constipation | Gastrointestinal disorders | Group A: Sargramostim (Days 1-14) | 0 | 8 | |
| other | Constipation | Gastrointestinal disorders | Group B: Sargramostim (3 x Week) | 1 | 9 | |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Group A: Sargramostim (Days 1-14) | 1 | 8 | |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Group B: Sargramostim (3 x Week) | 0 | 9 | |
| other | Creatinine, elevated | Investigations | Group A: Sargramostim (Days 1-14) | 0 | 8 | |
| other | Creatinine, elevated | Investigations | Group B: Sargramostim (3 x Week) | 2 | 9 | |
| other | Diarrhea patients without colostomy | Gastrointestinal disorders | Group A: Sargramostim (Days 1-14) | 1 | 8 | |
| other | Diarrhea patients without colostomy | Gastrointestinal disorders | Group B: Sargramostim (3 x Week) | 1 | 9 | |
| other | Dyspepsia/heartburn | Gastrointestinal disorders | Group A: Sargramostim (Days 1-14) | 1 | 8 | |
| other | Dyspepsia/heartburn | Gastrointestinal disorders | Group B: Sargramostim (3 x Week) | 0 | 9 | |
| other | Elevated SGOT (AST) (serum glutamic oxaloacetic transaminase) | Investigations | Group A: Sargramostim (Days 1-14) | 0 | 8 | |
| other | Elevated SGOT (AST) (serum glutamic oxaloacetic transaminase) | Investigations | Group B: Sargramostim (3 x Week) | 1 | 9 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00908141/events